Submitted:
20 June 2023
Posted:
20 June 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Conflicts of Interest
References
- Wu. F.; Zhao, S.; Yu, B.; Chen, Y.; Wang, W.; Song, Z.; et al. A new coronavirus associated with human respiratory disease in China. Nature 2020, 579(7798), 265-269. (accessed on 10 January 2022). [CrossRef]
- Yang, X.; Yu, Y.; Xu, J.; Shu, H.; Xia, J.; Liu, H.; et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020, 8(5), 475-481. (accessed on 10 January 2022). [CrossRef]
- Sohrabi, C.; Alsafi, Z.; O'Neill, N.; Khan, M.; Kerwan, A.; Al-Jabir, A.; et al. World health organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19). Int J Surg, 2020, 76, 71–76.
- World Health Organisation (WHO). WHO announces COVID-19 outbreak a pandemic 2020 . Available online: euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic. (accessed on 13 May 2021).
- Aćimović, J.; Jandrić, Lj.; Đaković Dević, J.; Bojanić, J.; Subotić, B.; Radojčić, T.; et al. Epidemiological characteristics of COVID-19 infection in the Republic of Srpska: a hundred days survey. Scr Med. 2020, 51(2), 74–80. [Google Scholar] [CrossRef]
- Durmus, V. Epidemic trends of COVID-19 in 10 countries compared with Turkey. Vacunas 2020, 22(1), 10–9. Available online; (accessed on 13 December 2021). [CrossRef]
- Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F.X.; Chong, M.; et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA 2020, 323(16), 1612-1614. (accessed on 13 December 2021)2020. [Google Scholar] [CrossRef]
- Lam, P.H.; Milam, A.J.; Tou, E.; Dhillon, N.K.; Toscano, S.; Abaalkhail, N. Characteristics of mechanically ventilated patients with COVID-19 and persons under investigation negative for COVID-19 at an academic medical center: A retrospective cross-sectional pilot study. J. Clin. Anesth. (accessed on 10 January 2022)2020; 67, 110029. [Google Scholar] [CrossRef]
- Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, KW. ; the Northwell COVID-19 Research Consor-tium; et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020, 323(20), 2052-2059. (accessed on 10 January 2022). [CrossRef]
- Booth, A.; Reed, A.B.; Ponzo, S.; Yassaee, A.; Aral, M.; Plans, D.; et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS ONE 2021, 16(3), e0247461. Available from; (accessed on 13 May 2021). [CrossRef]
- Krist, A.H.; DeVoe, J.E.; Cheng, A.; Ehrlich, T.; Jones, S.M. Redesigning primary care to address the COVID-19 pandemic in the midst of the pandemic. Ann Fam Med 2020, 18(4), 349-354. (accessed on 13 May 2021). [CrossRef]
- Mayer, M.A.; Vidal-Alaball, J.; Puigdellívol-Sánchez, A.; Gomez, F.X.M.; Leis, A.; Peña, J.M. Clinical Characterization of Patients With COVID-19 in Primary Care in Catalonia: Retrospective Observational Study. JMIR Public Health Surveill. 2021, 7(2), e25452. [Google Scholar] [CrossRef] [PubMed]
- Vahidy, F.S.; Pan, A.P.; Ahnstedt, H.; Munshi, Y.; Choi, H.A.; Tiruneh, Y.; et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: Cross-sectional analysis from a diverse US metropolitan area. PLoS ONE 2021, 16(1), e0245556. Available online; (accessed on 13 May 2021). [CrossRef]
- Hu, D.; Lou, X.; Meng, N.; Li, Z.; Teng, Y.; Zou, Y. Influence of age and gender on the epidemic of COVID-19, Evidence from 177 countries and territories—an exploratory, ecological study. Wien. Klin. Wochenschr. 2021, 133(7-8), 321-330. Available online; (accessed on 10 January 2022). [CrossRef]
- Liao J, Fan S, Chen J, Wu J, Xu S, Guo Y, et al. Epidemiological and Clinical Characteristics of COVID-19 in Adolescents and Young Adults. Intern. Jour. of Infect. Diseases 2021, 105, 113-119. (accessed on 10 January 2022). [CrossRef]
- Adab P, Haroon S, O’Hara M. E, Jordan R.E. Comorbidities and covid-19 Better understanding is essential for health system planning BMJ 2022, 377, o1431 (accessed on 13 May 2021) Available online:. [CrossRef]
- Djaharuddin I, Munawwarah S, Nurulita A, Ilyas M, Tabri N.A, Lihaw N. Comorbidities and mortality in COVID-19 patients. Gac. Sanit. 2021, 35(S2), S530–S532.
- Harizi C, Cherif I, Najar N, Osman M, Mallekh R, Ben Ayed O, et al. Characteristics and prognostic factors of COVID-19 among infected cases: a nationwide Tunisian analysis. BMC Infect. Di. 2021, 21, 140. Available online; (accessed on 13 May 2021). [CrossRef]
- Mijović, B.; Mašić, S.; Petković, M.; Knežević, D.; Aćimović, J.; Djaković-Dević, J.; et al. Seroprevalence of SARS-CoV-2 anti-bodies and knowledge, attitude and practice toward COVID-19 in the Republic of Srpska-Bosnia & Herzegovina: A population-based study. PLoS ONE 2022, 17(1), e0262738. Available online:; (accessed on 23 May 2021). [CrossRef]
- Zidan, N.; Dey, V.; Allen, K.; Price, J.; Zappone, S.R.; et al. Understanding comorbidities and health disparities related to COVID-19: a comprehensive study of 776 936 cases and 1 362 545 controls in the state of Indiana, USA. JAMIA Open 2023, 6(1). Available online:; (accessed on 13 May 2021). [CrossRef]
- Scientific Advisory Group. COVID-19 Scientific Advisory Group Rapid Evidence Report. Risk Factors for Severe COVID-19 Outcomes. Available online: https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-sag-rapid-evidence-report-masking-guidance-healthcare-workers. (accessed on 13 May 2021).
- Bigdelou, B.; Sepand, M.R.; Najafikhoshnoo, S.; Negrete, J.A.T.; Sharaf, M.; Ho, J.Q.; et al. COVID-19 and Preexisting Comorbidities: Risks, Synergies, and Clinical Outcomes. Front. Immunol. 2022, 13, 890517. [Google Scholar] [CrossRef] [PubMed]
- Miyashita, K.; Hozumi, H.; Furuhashi, K.; Nakatani, E.; Inoue, Y.; Yasui, H.; et al. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. Emerg. Microbes Infect. 2022, 12(1), e2155250. Available online:; (accessed on 13 May 2021). [CrossRef]
- Khedr, E.M.; Daef, E.; Mohamed-Hussein, A.; Mostafa, EF.; Zein, M.; Hassany, S.M.; et al. Comorbidities and outcomes among patients hospitalized with COVID-19 in Upper Egypt. Egypt. J. Neurol. Psychiatry Neurosurg. 2022, 58, 92 (accessed on 06 February 2022) Available online:. [Google Scholar] [CrossRef]
- Menezes Soares, R.C.; Rodrigues Mattos, L.; Martins Raposo, L. Risk Factors for Hospitalization and Mortality due to COVID-19 in Esp´ ırito Santo State, Brazil. Am. J. Trop. Med. Hyg. 2020, 103(3), 1184–1190. (accessed on 06 February 2022). [CrossRef]
- Wang, H.; Yu, M.; Ochani, M.; Amella, CA.; Tanovic, M.; Susarla, S.; et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421(6921), 384-388. (accessed on 10 January 2022). [CrossRef]
- Guo, F.R. Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): An update of a meta-analysis. Tob. Induc. Dis. 2020, 18, 37 (accessed on 10 January 2022). [Google Scholar] [CrossRef]
- Cai, G.; Bossé, Y.; Xiao, F.; Kheradmand, F.; Amos, CI. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am. J. Respir. Crit. Care Med. 2020, 201(12), 1557-1559. (accessed on 10 January 2022). [CrossRef]
- Leung, J.M.; Sin, D.D. Smoking, ACE-2 and COVID-19: ongoing controversies. Eur. Respir. J. 2020, 56(1), 2001759. (accessed on 10 January 2022). [CrossRef]
- World Health Organization. Resources for tobacco use control as part of COVID-19 response. URL: euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/publications-and-technicalguidance/resources-for-tobacco-use-control-as-part-of-covid-19-response.
- Hong, J-M.; Hu, L-H.; Zhong, Q-S.; Zhu, L-C.; Hang, Y-P.; Fang, X-Y.; et al. Epidemiological Characteristics and Clinical Features of Patients Infected With the COVID-19 Virus in Nanchang, Jiangxi, China. Front. Med. 2020; 7:571069. 13 May 2021. [CrossRef]
- Suleyman, G.; Fadel, R.A.; Malette, K.M.; Hammond, C.; Abdulla, H.; Entz, A.; et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Network Open. 2020, 3(6), e2012270. (accessed on 13 May 2021). [CrossRef]
- Kim, S.W.; Kim, S.M.; Kim, Y.K.; Kim, J.Y.; Lee, Y.M.; Kim, B.O.; et al. Characteristics of COVID-19 Cohort Patients in Daegu. J. Korean Med. Sci. 2021, 36(1), e12 Available online; (accessed on 13 May 2021)2021. [Google Scholar] [CrossRef]
- Mash, R.J.; Presence-Vollenhoven, M.; Adeniji, A.; Christoffels, R.; Doubell, K.; Eksteen, L.; et al. Evaluation of patient characteristics, management and outcomes for COVID-19 at district hospitals in the Western Cape, South Africa: descriptive observational study. BMJ Open 2021, 11, e047016. (accessed on 13 May 2021). [CrossRef]
- Boye, K.S.; Erdemir, E.T.; Zimmerman, N.; Reddy, A. Benneyworth B.D. Dabora M.C. Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States. Diabetes Ther. 2021, 12, 2223–2239. Available online; (accessed on 06 February 2022). [CrossRef]
- Lv, Z.; Lv, S. Clinical characteristics and analysis of risk factors for disease progression of COVID-19: A retrospective Cohort Study. Int. J. Biol. Sci. 2021, 17(1), 1-7. (accessed on 13 May 2021). [CrossRef]
- Goto, N.; Wada, Y.; Ikuyama, Y.; Akahane, J.; Kosaka, M.; Ushiki, A.; et al. The usefulness of a combination of age, body mass index, and blood urea nitrogen as prognostic factors in predicting oxygen requirements in patients with coronavirus disease 2019. J. Infect. Chemother. 2021, 27, 1706-1712. Available online; (accessed on 13 May 2021). [CrossRef]
- Vahey, G.M.; McDonald, E.; Marshall, K.; Martin, S. W:; Chun, H.; Herlihy, R.; et al. Risk factors for hospitalization among persons with COVID-19—Colorado. 2021; PLoS ONE 2021, 16(9), e0256917. Available online; (accessed on 06 February 2022). [CrossRef]
- Dreyer, N.; Petruski-Ivleva, N.; Albert, L.; Mohamed, D.; Brinkley, E.; Reynolds, M.; et al. Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19. Int. J. Gen. Med. 2021, 14, 3941–49. [Google Scholar] [CrossRef] [PubMed]
- Chatterjee, S.; Vineela Nalla, L.; Sharma, M.; Sharma, N.; Singh, A.A.; Mushtaque Malim, F.; et al. Association of COVID-19 with Comorbidities: An Update. ACS Pharmacol. Transl. Sci. 2023, 6(3), 334–354. [Google Scholar] [CrossRef] [PubMed]
- Nordström, P.; Ballin, M.; Nordström, A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022, S0140-6736(22)00089-7. [CrossRef]
- Graña, C.; Ghosn, L.; Evrenoglou, T.; Jarde, A.; Minozzi, S.; Bergman, H.; et al. Efficacy and safety of COVID-19 vaccines. CDSR 2022, 12. Art. No.: CD015477. Available online: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858. (accessed on 06 February 2022)0154. [Google Scholar]
- Seo, W.J.; Kanga, J.; Kanga, H.K.; Parka, S.H.; Kooa, H.K.; Park, H.K.; et al. Impact of prior vaccination on clinical outcomes of patients with COVID-19. Emerg. Microbes & Infect. 2022, 11. Available online; (accessed on 06 February 2022). [CrossRef]


| Total | Death | ||||||
| Hospitalization | Total | 2020 | 2021 | 2022 | |||
| Total | 3158 (92.2%) | 1569 (3.9%) | |||||
| Yeara | 2020 | 10724 (27.3%) | 1273 (11.9%) | 479 (4.5%) | |||
| 2021 | 20430 (51.9%) | 1786 (8.7%) | 896 (4.4%) | ||||
| 2022 | 8187 (20.8%) | 38 (0.5%) | 194 (2.4%) | ||||
| Agea | <10 | 819 (2%) | 21 (2.6%) | 0 | 0 (0%) | 0 (0%) | 0 (0%) |
| 10-19 | 2469 (6.1%) | 13 (0.5%) | 0 | 0 (0%) | 0 (0%) | 0 (0%) | |
| 20-29 | 4490 (11%) | 66 (1.5%) | 5 (0.1%) | 0 (0%) | 4 (0.2%) | 1 (0.1%) | |
| 30-39 | 7550 (18.6%) | 168 (2.2%) | 13 (0.2%) | 3 (0.1%) | 10 (0.3%) | 0 (0%) | |
| 40-49 | 7871 (19.4%) | 310 (3.9%) | 36 (0.5%) | 12 (0.5%) | 20 (0.5%) | 4 (0.3%) | |
| 50-59 | 5745 (14.1%) | 421 (7.3%) | 103 (1.8%) | 36 (2.3%) | 56 (2.0%) | 11 (1.0%) | |
| 60-69 | 6085 (15%) | 832 (13.7%) | 269 (4.4%) | 98 (6.2%) | 146 (4.6%) | 25 (2.2%) | |
| 70-79 | 3830 (9.4%) | 798 (20.8%) | 539 (14.1%) | 160 (17.8%) | 325 (15.7%) | 54 (7.5%) | |
| 80+ | 1810 (4.5%) | 526 (29.1%) | 603 (33.3%) | 170 (35.0%) | 334 (37.0%) | 99 (27.0%) | |
| Gender | Male | 19307 (47.4%) | 1891 (9.8%) | 925 (4.8%) | 317 (5.7%) | 504 (5.4%) | 104 (2.8%) |
| Female | 21385 (52.6%) | 1267 (5.9%) | 644 (3%) | 162 (3.1%) | 392 (3.5%) | 90 (2.0%) | |
| Total | Hospitalization | Death | ||
|---|---|---|---|---|
| Smoking | no | 36700 (90.2%) | 2917 (7.9%) | 1437 (3.9%) |
| yes | 3992 (9.8%) | 241 (6%)* | 132 (3.3%) | |
| Obesity | no | 35751 (87.9%) | 2483 (6.9%) | 1254 (3.5%) |
| yes | 4941 (12.1%) | 675 (13.7%)* | 315 (6.4%)* | |
| Hypercholesterolemia | no | 35759 (87.9%) | 2466 (6.9%) | 1258 (3.5%) |
| yes | 4933 (12.1%) | 692 (14%)* | 311 (6.3%)* | |
| HTA | no | 30638 (75.3%) | 1510 (4.9%) | 514 (1.7%) |
| yes | 10054 (24.7%) | 1648 (16.4%)* | 1055 (10.5%)* | |
| DM | no | 37402 (91.9%) | 2462 (6.6%) | 1131 (3%) |
| yes | 3290 (8.1%) | 696 (21.2%)* | 438 (13.3%)* | |
| Heart comorbidities | no | 38567 (94.8%) | 2726 (7.1%) | 1203 (3.1%) |
| yes | 2125 (5.2%) | 432 (20.3%)* | 366 (17.2%)* | |
| CRF | no | 40462 (99.4%) | 3090 (7.6%) | 1511 (3.7%) |
| yes | 230 (0.6%) | 68 (29.6%)* | 58 (25.2%)* | |
| Cancer | no | 38404 (94.4%) | 2804 (7.3%) | 1319 (3.4%) |
| yes | 2288 (5.6%) | 354 (15.5%)* | 250 (10.9%)* | |
| Vaccination | no | 29785 (73.2%) | 2025 (6.8%) | 1319 (4.4%) |
| yes | 10907 (26.8%) | 1133 (10.4%)* | 250 (2.3%)* | |
| Dose number | 1 | 587 (5.4%) | 67 (11.4%)* | 29 (4.9%)* |
| 2 | 8844 (81.1%) | 856 (9.7%) | 207 (2.3%) | |
| 2 + booster | 1267 (11.6%) | 195 (15.4%) | 14 (1.1%) | |
| booster only | 209 (1.9%) | 15 (7.2%) | 0 |
| Total | Hospitalization | Death Outcome | ||
|---|---|---|---|---|
| Fever | no | 11937 (39%) | 906 (7.6%) | 452 (3.8%) |
| yes | 18635 (61%) | 2116 (11.4%)* | 634 (3.4%) | |
| Cough | no | 18531 (60.6%) | 1629 (8.8%) | 650 (3.5%) |
| yes | 12043 (39.4%) | 1394 (11.6%)* | 436 (3.6%) | |
| Fatigue | no | 18407 (60.2%) | 1557 (8.5%) | 591 (3.2%) |
| yes | 12167 (39.8%) | 1466 (12%)* | 495 (4.1%)* | |
| Throat pain | no | 26061 (85.2%) | 2826 (10.8%) | 1029 (3.9%) |
| yes | 4513 (14.8%) | 197 (4.4%)* | 57 (1.3%)* | |
| Loss of smell and taste | no | 23652 (77.4%) | 2817 (11.9%) | 1043 (4.4%) |
| yes | 6922 (22.6%) | 206 (3%)* | 43 (0.6%)* | |
| Headache | no | 23223 (76%) | 2665 (11.5%) | 994 (4.3%) |
| yes | 7351 (24%) | 358 (4.9%)* | 92 (1.3%)* | |
| Diarrhea | no | 28586 (93.5%) | 2822 (9.9%) | 1019 (3.6%) |
| yes | 1988 (6.5%) | 201 (10.1%) | 67 (3.4%) | |
| Nausea, vomiting | no | 29867 (97.7%) | 2899 (9.7%) | 1060 (3.5%) |
| yes | 707 (2.3%) | 124 (17.5%)* | 26 (3.7%) | |
| Myalgia, arthralgia | no | 27803 (90.9%) | 2795 (10.1%) | 1028 (3.7%) |
| yes | 2771 (9.1%) | 228 (8.2%)* | 58 (2.1%)* | |
| Chest pain, shortness of breath | no | 30215 (98.8%) | 2961 (9.8%) | 1072 (3.5%) |
| yes | 359 (1.2%) | 62 (17.3%)* | 14 (3.9%) | |
| Appetite lost | no | 30014 (98.2%) | 2873 (9.6%) | 1038 (3.5%) |
| yes | 560 (1.8%) | 150 (26.8%)* | 48 (8.6%)* | |
| Rhinitis | no | 29520 (96.6%) | 2992 (10.1%) | 1080 (3.7%) |
| yes | 1054 (3.4%) | 31 (2.9%)* | 6 (0.6%)* |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).